Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

ANI Pharmaceuticals, Inc. (ANIP)

-NasdaqGM
25.55 Up 0.76(3.07%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette, MN 56623
United States - Map
Phone: 218-634-3500
Fax: 218-634-3540
Website: http://www.anipharmaceuticals.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:81

Business Summary 

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company offers generic products, including Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema for the treatment of ulcerative colitis; Metoclopramide syrup for treating heartburn symptoms with gastroesophageal reflux disease; and Opium Tincture to treat severe diarrhea by slowing the movement of the intestines, as well as branded products, such as Cortenema and Reglan tablets. It also provides contract manufacturing for various branded and generic companies. The company markets its products through wholesalers, retail market chains, distributors and mail order pharmacies, and hospitals. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on ANI Pharmaceuticals, Inc.

Key Executives 
 PayExercised
Mr. Arthur S. Przybyl , 57
Chief Exec. Officer, Pres and Director
593.00K0.00
Ms. Charlotte C. Arnold CPA, 49
Chief Financial Officer, VP, Sec. and Director
333.00K0.00
Mr. James G. Marken , 51
VP of Operations
205.00K0.00
Mr. Robert Schrepfer , 42
VP of New Bus. Devel. & Contract Manufacturing
194.00K0.00
Mr. Robert Joseph Jamnick , 56
VP of Quality & Product Devel.
175.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders